高管减持、管理层动荡、业绩转亏：卫宁健康面临多重压力

Governance Risks - The company has experienced significant executive turnover, with the former chairman sentenced to 18 months in prison for bribery, leading to a change in leadership [2] - Executives, including director Jin Mao, have engaged in concentrated share sell-offs, raising over 16 million yuan, which occurred around the time of the company's profit warning, raising concerns about their confidence in the company's future [1][2] Operational Risks - The company has projected a net loss of 320 million to 390 million yuan for 2025, a shift from profit in the previous year, with non-recurring losses impacting net profit by approximately 16 million yuan [1][2] - Factors contributing to the decline in performance include macroeconomic conditions, industry demand fluctuations, intensified market competition, and challenges in scaling revenue from the WiNEX product [2][3] Future Challenges - The company has outlined a development plan for 2026, focusing on AI integration in WiNEX products, improving delivery efficiency, and establishing an AI medical division, indicating a strategic pivot [3] - However, the effectiveness of these strategies remains uncertain due to ongoing governance issues and market conditions, alongside the need to rebuild trust in governance and investor relations [3][4]